Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea

Metabolism: Clinical and Experimental

Volumn 55, Issue 8, 2006, Pages 1076-1082

  Vgontzas, Alexandros N ^a   Trakada, Georgia ^a   Bixler, Edward O ^a   Lin, Hung Mo ^a   Pejovic, Slobodanka ^a   Zoumakis, Emmanuel ^b   Chrousos, George P ^b   Legro, Richard S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPOXIA; INSULIN RESISTANCE; OBESITY; OVARY POLYCYSTIC DISEASE; POLYSOMNOGRAPHY; PRIORITY JOURNAL; REGRESSION ANALYSIS; SLEEP APNEA SYNDROME; STATISTICAL SIGNIFICANCE;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CYTOKINES; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; OBESITY; POLYCYSTIC OVARY SYNDROME; POLYSOMNOGRAPHY; RESPIRATORY FUNCTION TESTS; SLEEP APNEA SYNDROMES; TESTOSTERONE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745823169     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.04.002     Document Type: Article

References (33)

1. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18 (1997) 774-800
2. Vgontzas A., Legro R., Bixler E., et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab 86 (2001) 517-520
3. Fogel R., Malhotra A., Pillar G., et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 86 (2001) 1175-1178
4. Gopal M., Duntley S., Uhles M., et al. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients with polycystic ovarian syndrome. Sleep Med 3 (2001) 401-404
5. Vgontzas A., and Chrousos G. Sleep-disordered breathing, sleepiness, and insulin resistance: is the latter a consequence, a pathogenetic factor or both?. Sleep Med 3 (2001) 389-391
6. Jaffe R. Polycystic ovary syndrome is associated with obstructive sleep apnoea and daytime sleepiness: role of insulin resistance. Obstet Gynecol Surv 56 (2001) 418-419
7. Vgontzas A., Papanicolaou D., Bixler E., et al. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J Clin Endocrinol Metab 82 (1997) 1313-1316
8. Vgontzas A., Papanicolaou D., Bixler E., et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab 85 (2000) 1151-1158
9. Mills P., and Dimsdale J. Sleep apnea: a model for studying cytokines, sleep and sleep disruption. Brain Behav Immun 18 (2004) 298-303
10. Vgontzas A., Bixler E., and Chrousos G. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med 254 (2003) 32-44
11. Gonzalez F., Thusu K., Abdel-Rahman E., et al. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome. Metabolism 48 (1999) 437-441
12. Sayin N., Gucer F., Balkanli-Kaplan P., et al. Elevated serum TNF-alpha levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med 48 (2003) 165-170
13. Amato G., Conte M., Mazziotti G., et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles. Obstet Gynecol 101 (2003) 1177-1182
14. Pellicer A., Albert C., Mercader A., et al. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril 71 (1999) 482-489
15. Escobar-Morreale H., Villuendas G., Botella-Carretero J., et al. Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 46 (2003) 625-633
16. Legro R., Kunselman A., Dodson W., et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 84 (1999) 165-169
17. Rechtschaffen A., and Kales A. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects (1968), U.S. Government Printing Office, Washington (DC) [NIMH Publication 204]
18. Dunaif A., Scott D., Finegood D., et al. The insulin-sensitizing agent. J Clin Endocrinol Metab 81 (1996) 3299-3306
19. Tremblay R., and Dube J. Plasma concentrations of free and non-TeBG bound testosterone in women on oral contraceptives. Contraception 10 (1974) 599-605
20. Littell R.C., Milliken G.A., Stroup W.W., and Wolfinger R.D. Heterogeneous variances. SAS system for mixed models (2002), SAS Institute, Cary (NC)
21. Tasali E., Van Cauter E., and Ehrmann A.D. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrine Metab 91 (2006) 36-42
22. Möhlig M., Spranger J., Osterhoff M., et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. Eur J Endocrinol 150 (2004) 525-532
23. Puder J.J., Freda P.U., Goland R.S., et al. Estrogen modulates the hypothalamic-pituitary-adrenal and inflammatory cytokine responses to endotoxin in women. J Clin Endocrinol Metab 86 (2001) 2403-2408
24. In: Tolis G., Bringer J., and Chrousos G.P. (Eds). Intraovarian regulators and the polycystic-ovary syndrome. Ann N Y Acad Sci vol. 687 (1993), New York, New York Academy of Sciences
25. Fried S., Bunkin D., and Greenberg A. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 83 (1998) 847-850
26. Vgontzas A.N., Zoumakis M., Bixler E.O., et al. Impaired nighttime sleep in healthy old versus young adults is associated with elevated plasma interleukin-6 and cortisol levels: physiologic and therapeutic implications. J Clin Endocrinol Metab 88 (2003) 2087-2095
27. Harris T.M., Ferrucci L., Tracy R.P., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 106 (1999) 506-512
28. Ridker P.M., Rifai N., Stampfer M.J., and Hennekens C.H. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 101 (2000) 1767-1772
29. Luc G., Bard J.M., Juhan-Vague I., et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME study. Arterioscler Throm Vasc Biol 23 (2003) 1255-1261
30. Roubenoff R., Parise H., Payette H.A., et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med 115 (2003) 429-435
31. Cappola A.R., Xue Q.L., Ferrucci L., Guralnik J.M., Volpato S., and Fried L.P. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab 88 (2003) 2019-2025
32. Volpato S., Pahor M., Ferrucci L., et al. Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults: the Healthy, Aging, and Body Composition study. Circulation 109 (2004) 607-612
33. Vgontzas A., Zoumakis E., Lin H.-M., et al. Marked decrease in sleepiness in patients with sleep apnea by etanercept, a tumor necrosis factor-a antagonist. J Clin Endocrinol Metab 89 (2004) 4409-4413